Itraconazole Dosing and Side Effects
For most systemic fungal infections, itraconazole should be initiated with a loading dose of 200 mg three times daily for 3 days, followed by 200 mg once or twice daily for maintenance therapy, with serum levels monitored after at least 2 weeks to ensure adequate drug exposure. 1
Recommended Dosing Schedules
Standard Dosing for Systemic Fungal Infections
Loading Phase:
- 200 mg orally three times daily for 3 days 1
Maintenance Phase:
- Mild to moderate disease: 200 mg once or twice daily for 6-12 months 1
- Severe disease or osteoarticular involvement: 200 mg twice daily for at least 12 months 1
- CNS infections: 200 mg 2-3 times daily for at least 12 months 1
Formulation-Specific Considerations
The oral solution is preferred over capsules when tolerated due to superior absorption characteristics 2. However, key differences exist:
- Capsules: Take with food; avoid antacids and proton pump inhibitors 2
- Solution: Take on empty stomach for optimal absorption 2, 3
- These formulations are NOT interchangeable 3
Oropharyngeal/Esophageal Candidiasis
- Oropharyngeal: 200 mg (20 mL solution) daily for 1-2 weeks 3
- Esophageal: 100 mg (10 mL solution) daily for minimum 3 weeks, continuing 2 weeks after symptom resolution 3
Necessary Monitoring
Therapeutic Drug Monitoring (TDM)
Serum levels must be checked after at least 2 weeks of therapy to ensure adequate drug exposure 1. This is critical because:
- Variable absorption occurs, particularly with capsule formulations 4, 5
- Pediatric patients and those with GI dysfunction have unpredictable pharmacokinetics 6
- Drug interactions significantly alter itraconazole concentrations 3
Target Concentrations
Combined itraconazole + hydroxy-itraconazole trough: >1.5 mcg/mL 6
Alternatively:
- Itraconazole parent compound alone: >0.5-1.0 mcg/mL 1, 6
- For treatment efficacy: minimum 0.5 mcg/mL 7
- For prophylaxis: minimum 0.25 mcg/mL 7
- Toxicity risk increases at >3 mcg/mL 6
Critical caveat: Studies show that 82% of patients on standard dosing have subtherapeutic levels initially 4. In one study, only 11% achieved adequate concentrations with standard capsule dosing 4. Dose adjustment is frequently necessary but often overlooked—in one series, only 28.6% of patients with subtherapeutic levels had doses appropriately increased 5.
Hepatic Monitoring
- Baseline liver function tests before initiating therapy 3
- Monitor liver enzymes during treatment, especially in patients with pre-existing hepatic abnormalities 3
- Hepatotoxicity occurs in approximately 6.5% of patients 5
Common Adverse Effects
Gastrointestinal Effects
- Most frequent adverse events: nausea, vomiting, diarrhea (15.2% of treatment courses) 5
- Oral solution causes more GI symptoms than capsules due to excipient (hydroxypropyl-β-cyclodextrin) 2
Hepatotoxicity
- Occurs in 6.5% of patients 5
- Not clearly associated with elevated trough levels 5
- Requires immediate discontinuation if symptomatic or significant enzyme elevation occurs 3
Cardiovascular Effects
- Peripheral edema 8
- Drug-induced hypertension 8
- Negative inotropic effects—contraindicated in heart failure 3
Other Notable Effects
- Hypokalemia and hypomagnesemia (monitor electrolytes)
- Rash (uncommon, may require discontinuation) 9
- Hearing loss (particularly in elderly patients, especially with concurrent quinidine use) 3
Long-Term Toxicity Concerns
- Bone effects: Animal studies show reduced bone plate activity and increased fragility at therapeutic doses 3
- Dental effects: Hypocellular tooth pulp in animal studies 3
- Clinical significance in humans unknown, but warrants caution with prolonged therapy (>6 months) 3
Critical Drug Interactions
Contraindicated Medications
Multiple drugs are absolutely contraindicated with itraconazole due to life-threatening interactions 3:
- Certain statins, calcium channel blockers, antiarrhythmics (see full prescribing information)
- Quinidine (associated with hearing loss in elderly) 3
Drugs That Decrease Itraconazole Levels (Avoid)
- Rifampin, rifabutin: Not recommended 2 weeks before, during, and 2 weeks after therapy 3
- Phenytoin, phenobarbital, carbamazepine: Not recommended 3
- Efavirenz, nevirapine: Not recommended 3
- Proton pump inhibitors with capsules (but not solution) 3
Drugs That Increase Itraconazole Levels
- Ritonavir, cobicistat, clarithromycin: Monitor for toxicity; dose reduction may be necessary 3
Special Populations
Pediatric Patients
- Children ≤12 years require higher doses: median 6.2 mg/kg/day vs 3.9 mg/kg/day in older children 5
- 71.4% of children ≤12 years need doses >5 mg/kg/day to achieve therapeutic levels 5
- Long-term bone effects unknown; use with caution 3
Renal Impairment
- Lower exposure may occur; dose adjustment may be needed 3
- Monitor levels closely and adjust accordingly
Hepatic Impairment
- Use with extreme caution; prolonged half-life observed 3
- Strongly discouraged unless life-threatening infection where benefit exceeds risk 3
- Mandatory liver function monitoring if used 3
Pregnancy
- Contraindicated unless life-threatening infection 3
- Teratogenic in animal studies (skeletal defects, encephaloceles) 3
- Highly effective contraception required during and for 2 months after therapy 3
Key Clinical Pitfalls
Assuming therapeutic levels without TDM: The majority of patients on standard dosing have inadequate levels 4
Not adjusting doses when levels are low: Despite frequent subtherapeutic levels, dose adjustments are often not made 5
Interchanging formulations: Capsules and solution are NOT bioequivalent and should never be substituted 3
Ignoring drug interactions: Itraconazole has extensive CYP3A4 interactions requiring careful medication review 3
Inadequate treatment duration: Most infections require 6-12 months minimum; osteoarticular and CNS infections need ≥12 months 1
Using capsules with acid-suppressing agents: This dramatically reduces absorption; switch to solution if PPIs are necessary 2, 3